336 related articles for article (PubMed ID: 9259775)
61. Semi-allogeneic dendritic cells injected via the intratumoural injection route show efficient antitumour effects in cooperation with host-derived professional antigen-presenting cells.
Kondoh H; Okano S; Yoshida K; Yonemitsu Y; Tomita Y; Yoshikai Y; Wake N; Sueishi K
Scand J Immunol; 2010 Dec; 72(6):476-90. PubMed ID: 21044122
[TBL] [Abstract][Full Text] [Related]
62. Targeting dendritic cells with antigen via dendritic cell-associated promoters.
Moulin V; Morgan ME; Eleveld-Trancikova D; Haanen JB; Wielders E; Looman MW; Janssen RA; Figdor CG; Jansen BJ; Adema GJ
Cancer Gene Ther; 2012 May; 19(5):303-11. PubMed ID: 22361816
[TBL] [Abstract][Full Text] [Related]
63. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen.
Xia D; Zheng S; Zhang W; He L; Wang Q; Pan J; Zhang L; Wang J; Cao X
J Mol Med (Berl); 2003 Sep; 81(9):585-96. PubMed ID: 12937899
[TBL] [Abstract][Full Text] [Related]
64. Pulsing of dendritic cells with cell lysates from either B16 melanoma or MCA-106 fibrosarcoma yields equally effective vaccines against B16 tumors in mice.
DeMatos P; Abdel-Wahab Z; Vervaert C; Hester D; Seigler H
J Surg Oncol; 1998 Jun; 68(2):79-91. PubMed ID: 9624036
[TBL] [Abstract][Full Text] [Related]
65. Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes.
Porgador A; Gilboa E
J Exp Med; 1995 Jul; 182(1):255-60. PubMed ID: 7540653
[TBL] [Abstract][Full Text] [Related]
66. Murine epidermal Langerhans cells and splenic dendritic cells present tumor-associated antigens to primed T cells.
Cohen PJ; Cohen PA; Rosenberg SA; Katz SI; Mulé JJ
Eur J Immunol; 1994 Feb; 24(2):315-9. PubMed ID: 7905414
[TBL] [Abstract][Full Text] [Related]
67. Antitumor reactivity of splenocytes primed in vivo with dendritic-cell-based vaccine and secondarily activated with a cocktail of cytokines in vitro.
Zhang S; Li WF; Zhang HJ; Wang Q
Exp Oncol; 2004 Sep; 26(3):243-5. PubMed ID: 15494696
[TBL] [Abstract][Full Text] [Related]
68. A defined serum-free medium useful for monitoring anti-melanoma responses induced by dendritic cell immunotherapy.
Bouwer AL; Netter P; Kemp RA; McLellan AD
J Immunol Methods; 2010 Jan; 352(1-2):178-81. PubMed ID: 19903484
[TBL] [Abstract][Full Text] [Related]
69. Antitumor effect of interferon plus cyclosporine A following chemotherapy for disseminated melanoma.
Charak BS; Sadowski RM; Mazumder A
Cancer Res; 1992 Dec; 52(23):6482-6. PubMed ID: 1384963
[TBL] [Abstract][Full Text] [Related]
70. Effective adoptive transfer of haploidentical tumor-specific T cells in B16-melanoma bearing mice.
Cui NP; Xie SJ; Han JS; Ma ZF; Chen BP; Cai JH
Chin Med J (Engl); 2012 Mar; 125(5):794-800. PubMed ID: 22490577
[TBL] [Abstract][Full Text] [Related]
71. Peroxynitrite-dependent killing of cancer cells and presentation of released tumor antigens by activated dendritic cells.
Fraszczak J; Trad M; Janikashvili N; Cathelin D; Lakomy D; Granci V; Morizot A; Audia S; Micheau O; Lagrost L; Katsanis E; Solary E; Larmonier N; Bonnotte B
J Immunol; 2010 Feb; 184(4):1876-84. PubMed ID: 20089706
[TBL] [Abstract][Full Text] [Related]
72. Breaking self-tolerance to tumor-associated antigens by in vivo manipulation of dendritic cells.
Mende I; Engleman EG
Methods Mol Biol; 2007; 380():457-68. PubMed ID: 17876112
[TBL] [Abstract][Full Text] [Related]
73. Generation and characterization of IL-2-activated bone marrow cells as a potent graft vs tumor effector in transplantation.
Agah R; Malloy B; Kerner M; Mazumder A
J Immunol; 1989 Nov; 143(9):3093-9. PubMed ID: 2809219
[TBL] [Abstract][Full Text] [Related]
74. Antigen-containing liposomes engrafted with flagellin-related peptides are effective vaccines that can induce potent antitumor immunity and immunotherapeutic effect.
Faham A; Altin JG
J Immunol; 2010 Aug; 185(3):1744-54. PubMed ID: 20610649
[TBL] [Abstract][Full Text] [Related]
75. Rejection of a nonimmunogenic melanoma by vaccination with natural melanoma peptides on engineered antigen-presenting cells.
Bellone M; Iezzi G; Martin-Fontecha A; Rivolta L; Manfredi AA; Protti MP; Freschi M; Dellabona P; Casorati G; Rugarli C
J Immunol; 1997 Jan; 158(2):783-9. PubMed ID: 8992995
[TBL] [Abstract][Full Text] [Related]
76. Enhanced therapeutic efficacy of tumor RNA-pulsed dendritic cells after genetic modification with lymphotactin.
Zhang W; He L; Yuan Z; Xie Z; Wang J; Hamada H; Cao X
Hum Gene Ther; 1999 May; 10(7):1151-61. PubMed ID: 10340547
[TBL] [Abstract][Full Text] [Related]
77. The maturation of murine bone marrow-derived dendritic cells by tumor lysate uptake in vitro is not essential for cancer immunotherapy.
Woo SC; Kim GY; Lee CM; Moon DO; Kim HK; Lee TH; Moon YS; Park NC; Yoon MS; Lee KS; Park YM
Cancer Biol Ther; 2005 Dec; 4(12):1331-5. PubMed ID: 16322691
[TBL] [Abstract][Full Text] [Related]
78. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo.
Paglia P; Chiodoni C; Rodolfo M; Colombo MP
J Exp Med; 1996 Jan; 183(1):317-22. PubMed ID: 8551239
[TBL] [Abstract][Full Text] [Related]
79. Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma.
Bellone M; Cantarella D; Castiglioni P; Crosti MC; Ronchetti A; Moro M; Garancini MP; Casorati G; Dellabona P
J Immunol; 2000 Sep; 165(5):2651-6. PubMed ID: 10946294
[TBL] [Abstract][Full Text] [Related]
80. CD40 triggering increases the efficiency of dendritic cells for antitumoral immunization.
Mazouz N; Ooms A; Moulin V; Van Meirvenne S; Uyttenhove C; Degiovanni G
Cancer Immun; 2002 Mar; 2():2. PubMed ID: 12747747
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
